# Levetiracetam

Source: https://onco.cc/drugs/levetiracetam/  
OnCo record `levetiracetam` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Levetiracetam is an anti-seizure medicine. After CAR-T cell therapy it is the recommended treatment for seizures, and some people at high risk of nerve side effects take it to prevent them.

## Summary

The Keppra label covers partial-onset seizures from 1 month of age and, as adjunctive therapy, myoclonic seizures in juvenile myoclonic epilepsy and primary generalised tonic-clonic seizures. SITC 2020: "To manage seizures in patients treated with CAR T cell therapies, levetiracetam is recommended (LE: 4)"; there is insufficient evidence for prophylaxis in everyone, but "in patients deemed to be at high-risk of developing neurotoxicity ... prophylactic levetiracetam may be considered". The NDA was first approved on 30 November 1999.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-11-11
- Tags: supportive; generic; supportive-care-gaps-2026-11
- Brand: Keppra
- Modality: Antiepileptic (oral, intravenous)
- Mechanism: An antiepileptic that binds synaptic vesicle protein SV2A.
- Approvals: US 1999: Partial-onset seizures; adjunctive treatment of myoclonic and primary generalised tonic-clonic seizures

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Levetiracetam
- US label (DailyMed): Keppra: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ca9df05-a506-4ec8-a4fe-320f1219ab21
- Maus et al., SITC clinical practice guideline on immune effector cell-related adverse events (J Immunother Cancer 2020): https://doi.org/10.1136/jitc-2020-001511

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- terms: [ICANS (neurotoxicity)](https://onco.cc/terms/icans/)

---
JSON: https://onco.cc/api/v1/entities/levetiracetam.json